REGN20423 / Regeneron - LARVOL DELTA

REGN20423: A fully human long-acting IL‑13 specific antibody with ultra‑high affinity, potent efficacy and extended half‑life (EADV 2026) - No abstract available

Clinical • IL13

AURA-AD: First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis (clinicaltrials.gov) - P1 | N=144 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13 • POSTN

R20423-HV-2555: First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis (clinicaltrialsregister.eu) - P1 | N=64 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals Inc.

First-in-human • New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

AURA-AD: First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis (clinicaltrials.gov) - P1 | N=136 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals

First-in-human • New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13 • POSTN